Cell-free DNA in Acute Stroke

CANTO - Cell-free DNA in Acute Stroke

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06928675

Acronym

CANTO

Enrollment

200

Registered

2025-04-15

Start date

2025-03-30

Completion date

2026-09-01

Last updated

2025-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Keywords

cell-free DNA, stroke etiologies, reperfusion, secondary emboli, stroke subtypes

Brief summary

Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan) * 18 years of age

Exclusion criteria

* Patients currently undergoing immunological therapies. * Patients with immunological diseases * Patients with systemic infections at the time of admission

Design outcomes

Primary

Measure	Time frame	Description
Stroke Etiology	at day 1	Descriptive comparison of cell-free DNA in cerebral thrombi regarding stroke etiology

Secondary

Measure	Time frame	Description
Correlation cfDNA concentration and perfusion outcome	at day 1	cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including perfusion outcome
Correlation cfDNA concentration and secondary embolism	at day 1	cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including secondary embolism
Correlation cfDNA concentration and thrombus fragmentation.	at day 1	cfDNA abount in blood and thromi is assessed in relation to thrombectomy outcomes including thrombus fragmentation
Measures of cfDNA as a marker of systemic inflammation	at day 1	to correlate cfDNA amount in blood and thrombi
90-day functional outcomes	up to 3 month	to examine the association between cfDNA concentrations in blood and thrombi with 90-day functional outcomes. To assess functional outcomes, the modified Rankin Scale (mRS) is evaluated via a structured telephone interview on day 90. A favorable outcome is defined as an mRS score of 0 to 2 points, while an unfavorable outcome is defined as an mRS score of 3 to 5 points.

Countries

Switzerland

Contacts

Primary ContactGerrit Grosse, PD Dr. Dr.

gerrit.grosse@usb.ch+41 61 32 85265

Outcome results